| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 4247.3 | 4018.5 | 6046.9 |
| Other income | 2.5 | 65.8 | 200.6 |
| Total income | 4249.9 | 4084.2 | 6247.5 |
| Profit before exceptional items & tax | 622.2 | 643.4 | 2352.5 |
| Exceptional items | -283.9 | 0.0 | -1385.1 |
| Profit before tax | 338.3 | 643.4 | 967.4 |
| Net profit | 263.8 | 482.8 | 610.4 |
| Operating margin | 8.0% | 15.8% | 15.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -56.80% |
|---|---|
| Net profit, quarter on quarter | -45.40% |
| Revenue, year on year | -29.80% |
| Operating profit, year on year | -71.20% |
| Operating profit, quarter on quarter | +7.30% |
NSE results filing, NSE: GLENMARK. Figures extracted from the filing.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,481.80
- Market cap
- ₹70,043 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 39.0×Sector 37.9×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Results Update
Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.